Catalent snaps up Aptuit's trial supplies ops for $410M

Pumping up its clinical trial services muscle, Catalent Pharma announced it is buying Aptuit's clinical trial supply business for $410 million in cash. Aptuit, a contract research and manufacturing company which purchased GSK's R&D center in Verona, Italy last year, says the deal will allow the company to focus more closely on building its global discovery and development services operations. "This transaction builds important expertise, scale and capability for our development and clinical services business to better meet our customers' needs globally," said Catalent CEO John Chiminski in a statement. "This transaction also strengthens Catalent's global leadership in development solutions and advanced delivery technologies for drugs and biologics." Catalent release

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.